Theranostic probe and its use for targeting and/or labeling the EGFR kinase and/or the cells expressing EGFR or its family members

1 . A theranostic probe represented by formula (1):

Module 2-L-Module 1   (1)

wherein

L is a linker;

Module 1 is a moiety targeting the EGFR kinase and is represented by formula (2):

wherein

R 1 in formula (2) is H, halogen or C 2-6 alkynyl;

R 2 in formula (2) is H, halogen, C 6-10 arylC 1-6 alkyloxy or 5- to 6-membered heteroarylC 1-6 alkyloxy, wherein the C 6-10 aryl and 5- to 6-membered heteroaryl are optionally substituted with halogen, and the 5- to 6-membered heteroaryl comprises 1, 2, 3 or 4 heteroatoms selected from the group consisting of O, S and N;

R 3 in formula (2) is H, C 1-6 alkyloxy optionally substituted with C 1-6 alkyloxy, or 5- to 6-membered heterocycloalkyloxy, wherein the 5- to 6-membered heterocycloalkyl comprises 1 or 2 heteroatoms selected from the group consisting of O, S and N;

R 4 in formula (2), as the attachment point of Module 1 to L, is —(CH 2 ) n —; and

n in formula (2) is 0, 1, 2, 3, 4, 5 or 6; and

Module 2 is an imaging probe selected from the group consisting of fluorescent, MRI and radioactive probes;

or a theranostically acceptable salt thereof.

2 . The theranostic probe of claim 1 , wherein L is —C(O)O— or —C(O)NH—.

3 . The theranostic probe of claim 1 , wherein Module 2 is represented by formula (3) or (4):

wherein

R 1 in formula (3) or (4), as the attachment point of Module 2 to L, is —(CH 2 ) n —;

R 2 in formula (3) or (4) is —(CH 2 ) n CH 3 ; and

n in formula (3) or (4), at each occurrence, is independently 0, 1, 2, 3, 4, 5 or 6;

or Module 2 is represented by formula (5) or (6):

wherein

the symbol * in formula (5) or (6) represents the attachment point of Module 2 to L; and

n in formula (5) is independently 0, 1, 2, 3, 4, 5 or 6,

wherein if necessary, a counterion is present and selected from the group consisting of alkali metal and alkaline earth metal ions.

4 . The theranostic probe of claim 1 , represented by formula (7):

wherein a counterion is present and selected from the group consisting of alkali metal and alkaline earth metal ions.

5 . The theranostic probe of claim 1 , wherein the EGFR kinase has a mutation of L834R, V924R, V745M or combination of any two or three of L834R, V924R and V745M.

6 . The theranostic probe of claim 1 , wherein the EGFR kinase is present in a dimeric conformation.

7 . The theranostic probe of claim 1 , wherein the conformation of the EGFR kinase is associated with oncogenesis.

8 . The theranostic probe of claim 1 , wherein the conformation of the EGFR kinase is associated with prostate cancer.

9 . The theranostic probe of claim 1 , wherein the conformation of the EGFR kinase is associated with metastatic and/or castration-resistant prostate cancer.